The nitric oxide synthase inhibitor, L-NAME, blocks phencyclidine-induced disruption of prepulse inhibition in mice

被引:50
作者
Klamer, D [1 ]
Engel, JA [1 ]
Svensson, L [1 ]
机构
[1] Univ Gothenburg, Dept Pharmacol, S-40530 Gothenburg, Sweden
关键词
nitric oxide; prepulse inhibition; schizophrenia; phencyclidine; mice;
D O I
10.1007/s002130100783
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Schizophrenia is a major public health problem that affects approximately 1% of the population worldwide. Schizophrenia-like syndromes can be induced in humans by phencyclidine (PCP), a drug with marked psychomimetic properties. Recent studies show that the behavioural and biochemical effects of PCP in rats are blocked by nitric oxide synthase (NOS) inhibitors, suggesting that NO plays an important role in the pharmacological effects of PCP. Objective: The aim of this study was to investigate if PCP-induced disruption of prepulse inhibition of acoustic startle could be blocked by the NOS inhibitor, L-NAME, in mice. Results: The present study shows that PCP readily disrupts prepulse inhibition in mice normally without affecting pulse-alone trials. Furthermore, L-NAME blocked the PCP-induced disruption of prepulse inhibition in a dose-related manner. Conclusions: The PCP-induced disruption of prepulse inhibition and the ability of L-NAME to block this effect in both rats and mice suggest that this is a general and not a species-specific effect. The results of the present study further suggest that PCP exerts at least some of its actions in the central nervous system by a NO-dependent mechanism.
引用
收藏
页码:182 / 186
页数:5
相关论文
共 50 条
  • [21] CLOZAPINES EFFECTS ON PHENCYCLIDINE-INDUCED DISRUPTION OF PREPULSE INHIBITION OF THE ACOUSTIC STARTLE RESPONSE
    WILEY, JL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 49 (04) : 1025 - 1028
  • [22] Strain-Specificity in Nicotine Attenuation of Phencyclidine-Induced Disruption of Prepulse Inhibition in Mice: Relevance to Smoking in Schizophrenia Patients
    Cecile Spielewoy
    Athina Markou
    Behavior Genetics, 2004, 34 : 343 - 354
  • [23] Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: Relevance to smoking in schizophrenia patients
    Spielewoy, C
    Markou, A
    BEHAVIOR GENETICS, 2004, 34 (03) : 343 - 354
  • [24] The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits
    Losonczy, G
    Mucha, I
    Muller, V
    Kriston, T
    Ungvari, Z
    Tornoci, L
    Rosivall, L
    Venuto, R
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) : 1012 - 1018
  • [25] Involvement of nitric oxide in phencyclidine-induced place aversion and preference in mice
    Miyamoto, Y
    Noda, Y
    Komori, Y
    Sugihara, H
    Furukawa, H
    Nabeshima, T
    BEHAVIOURAL BRAIN RESEARCH, 2000, 116 (02) : 187 - 196
  • [26] Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice
    Issy, A. C.
    Salum, C.
    Del Bel, E. A.
    BEHAVIOURAL BRAIN RESEARCH, 2009, 205 (02) : 475 - 481
  • [27] Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats
    Yamada, S
    Harano, M
    Annoh, N
    Nakamura, K
    Tanaka, M
    BIOLOGICAL PSYCHIATRY, 1999, 46 (06) : 832 - 838
  • [28] Failure of L-NAME to cause inhibition of nitric oxide synthesis: Role of inducible nitric oxide synthase
    Miller, MJS
    Thompson, JH
    Liu, X
    ElobyChildress, S
    SadowskaKrowicka, H
    Zhang, XJ
    Clark, DA
    INFLAMMATION RESEARCH, 1996, 45 (06) : 272 - 276
  • [29] Nitric oxide synthase inhibition by L-NAME in streptozotocin induced diabetic rats:: Impacts on oxidative stress
    Seven, A
    Güzel, S
    Seymen, O
    Civelek, S
    Bolayirli, M
    Yigit, G
    Burçak, G
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 199 (04) : 205 - 210
  • [30] INVOLVEMENT OF NITRIC-OXIDE IN PHENCYCLIDINE-INDUCED HYPERLOCOMOTION IN MICE
    NODA, Y
    YAMADA, K
    FURUKAWA, H
    NABESHIMA, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (03) : 291 - 297